Zobrazeno 1 - 4
of 4
pro vyhledávání: '"JoAnn La Fargue"'
Autor:
Jaehyeon Park, Harlan F Reese, Yun-Chou Tan, Hasim Zecic, Martin Stahl, Keshab Sarma, Renee Litman, Alejandra Trejo, William Bingenheimer, Michael Soth, David Michael Goldstein, Mary Welch, Eric Brian Sjogren, Man-Ling Sung, Sandra Frauchiger, Nolan James Dewdney, Bong San Pablo, Eva Papp, Daniel McWeeney, Ronald J. Hill, Paul Weller, Manjiri Ghate, JoAnn La Fargue, Brian Wong, Stacie A. Dalrymple, James Patrick Dunn, David Mark Rotstein, Richard T. Roberts, Bradford Graves, Rebecca T Suttman, Mcintosh Joel, Farrell Robert P, Andreas Kuglstatter, Chen Jian Jeffrey, Fujun Li, Humberto Bartolome Arzeno, Brad Loe, Tobias Gabriel
Publikováno v:
Journal of Medicinal Chemistry. 54:2255-2265
The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bdfa3e0a0a96eaca0eea2feab67e249
https://doi.org/10.1021/jm101423y
https://doi.org/10.1021/jm101423y
Autor:
Suzanne K. Swan, Melvin Toh, May Garrett, Reza Khosravan, Grace Ni, Thomas Marbury, Norman M. Lunde, Carlo L. Bello, JoAnn La Fargue
Publikováno v:
The Journal of Clinical Pharmacology. 50:472-481
This phase I, open-label, single-dose study evaluates the effects of severe renal impairment and end-stage renal disease (ESRD) requiring hemodialysis on the pharmacokinetics, safety, and tolerability of sunitinib and its primary active metabolite, S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680d752dc3b91706c6d9105295bec1ec
https://doi.org/10.1177/0091270009347868
https://doi.org/10.1177/0091270009347868
Autor:
David M, Goldstein, Michael, Soth, Tobias, Gabriel, Nolan, Dewdney, Andreas, Kuglstatter, Humberto, Arzeno, Jeffrey, Chen, William, Bingenheimer, Stacie A, Dalrymple, James, Dunn, Robert, Farrell, Sandra, Frauchiger, JoAnn, La Fargue, Manjiri, Ghate, Bradford, Graves, Ronald J, Hill, Fujun, Li, Renee, Litman, Brad, Loe, Joel, McIntosh, Daniel, McWeeney, Eva, Papp, Jaehyeon, Park, Harlan F, Reese, Richard T, Roberts, David, Rotstein, Bong, San Pablo, Keshab, Sarma, Martin, Stahl, Man-Ling, Sung, Rebecca T, Suttman, Eric B, Sjogren, Yunchou, Tan, Alejandra, Trejo, Mary, Welch, Paul, Weller, Brian R, Wong, Hasim, Zecic
Publikováno v:
Journal of medicinal chemistry. 54(7)
The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cda31600d6054cc75ed83ea768d5f392
https://pubmed.ncbi.nlm.nih.gov/21375264
https://pubmed.ncbi.nlm.nih.gov/21375264
Autor:
Welch Teresa Rosanne, David Michael Goldstein, Stacie A. Dalrymple, Joann La Fargue, Jay Bertrand, Chakk Ramesha, Michelle F. Browner, Will Tao, Sheila Zipfel, Eva Papp, Alejandra Trejo, Kelly Young, Jose Freire-Moar, James Dunn, Susan Larrabee, Rick Roberts, Mary Welch, Daniel Mcweeney, Armando Villasenor, Jean Marc Lapierre, David Rotstein, On-Yee So, Sharada S. Labadie, Phyllis E. Whiteley, Ken Clifford, Bong San Pablo, Tom Alfredson, Seth Harris, Paul Weller, Eric B. Sjogren, Fujun Li, Francisco X. Mountain View Talamas
Publikováno v:
Journal of medicinal chemistry. 49(5)
A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74021732dae7f5fb513dc237543e3952
https://pubmed.ncbi.nlm.nih.gov/16509574
https://pubmed.ncbi.nlm.nih.gov/16509574